home / stock / chrs / chrs news

CHRS News and Press, Coherus BioSciences Inc. From 12/27/23

Stock Information
Company Name: Coherus BioSciences Inc.
Stock Symbol: CHRS
Market: NASDAQ
Website: coherus.com
Menu
CHRS CHRS Quote CHRS Short CHRS News CHRS Articles CHRS Message Board
Get CHRS Alerts

News, Short Squeeze, Breakout and More Instantly...
CHRS - 24/7 Market News Lunch Break 27 Dec 2023

2023-12-27 12:23:36 ET DENVER, Colo., Dec. 27, 2023 ( www.247marketnews.com )- The following companies published announcements or are trading higher on higher-than-usual midday volume; First Wave BioPharma Inc (NASDAQ: FWBI), Coherus BioSciences Inc (NASDAQ: CHRS), Cingulate Inc (NASDAQ...
CHRS - Making Waves- 24/7 Market News Snapshot 27 Dec 2023

2023-12-27 09:57:20 ET DENVER, Colo., Dec. 27, 2023 ( www.247marketnews.com )- The following companies published announcements or are trading higher on higher-than-usual volume; First Wave BioPharma Inc (NASDAQ: FWBI), Coherus BioSciences Inc (NASDAQ: CHRS), Opthea Ltd (NASDAQ: OPT), Ci...

CHRS - Another Biotech Massively Outperforms Broader Equities

2023-12-27 09:30:08 ET A California-based %Biotech company is stealing the show during Wednesday’s premarket after it was announced that the FDA approved Udenyca Onbody, a device used to deliver Udenyca for cancer patients. According to the release, the company intends to commerc...

CHRS - FDA Approval Announcement Fueling Strong Move

2023-12-27 09:25:38 ET DENVER, Colo., Dec 27, 2023 ( www.247marketnews.com )- Coherus BioSciences, Inc. (NASDAQ: CHRS) announced, after yesterday’s market close, that the U.S. Food and Drug Administration (FDA) approved UDENYCA ONBODY, the company’s on-body injector (OBI) ...
CHRS - Cytokinetics, Burford Capital, Cipher Mining among premarket gainers' pack

2023-12-27 08:27:59 ET First Wave BioPharma FWBI +107% on plans to sell niclosamide program . Cingulate ( CING ) +89% . Cytokinetics CYTK +53% on positive Phase 3 data for heart disease therapy . Jet.AI ( JTAI ) +38% . Cohe...

CHRS - Coherus Announces FDA Approval of UDENYCA ONBODY(TM), a Novel and Proprietary State-of-the-Art Delivery System for pegfilgrastim-cbqv

– Innovative design enables five-minute pegfilgrastim delivery time – – Unique, automatic, retractable needle mechanism engineered to maximize safety and comfort for cancer patients receiving pegfilgrastim – REDWOOD CITY, Calif., Dec. 26...

CHRS - 2 Small Cap Stocks That Could Go Parabolic in 2024, According to Wall Street

2023-12-24 09:45:00 ET Small-cap stocks have been under pressure ever since the Federal Reserve started hiking interest rates in the first quarter of 2022. As a result, scores of companies in this category sport rock-bottom valuations right now. With the Fed possibly set to reverse course o...
CHRS - BLUE,XERS and CHRS are among after hour movers

2023-12-18 17:21:05 ET Gainers: Xeris Biopharma Holdings ( XERS ) +4% . Intuitive Machines ( LUNR ) +3% . Century Aluminum Company ( CENX ) +3% . Coherus BioSciences ( CHRS ) +2% . Independent Bank ( INDB ) +2% . Losers: ...

CHRS - Coherus Announces Updated NCCN Clinical Practice Guidelines Positioning LOQTORZI(TM) (toripalimab-tpzi) as Preferred Category 1 Regimen for First-Line Treatment of Cancer of the Nasopharynx

– NCCN Guidelines recommend LOQTORZI as the only Preferred Category 1 treatment option in first-line treatment for adults with metastatic or recurrent locally advanced NPC in combination with chemotherapy; LOQTORZI monotherapy also recommended as the only preferred regimen in subsequent li...

CHRS - SVFD, ADTX and CHSN among pre-market losers

2023-12-08 08:27:04 ET More on pr-market losers $ stocks. Aditxt appoints Ernie Lee as CEO of its wholly-owned subsidiary, Pearsanta IPO Roundup: WeBuy Global, Maison Solutions and more Seeking Alpha’s Quant Rating on Aditx Therapeutics Historical earn...
Previous 10 Next 10